Sign in
Taking people in United StatesPhase 3

Tests sacituzumab tirumotecan for previously untreated triple-negative breast cancer

Tests sacituzumab tirumotecan, alone or with pembrolizumab, in adults with triple-negative breast cancer.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Albuquerque, Altamonte Springs, Athens, Baltimore, Boise, Chandler, Chicago, Clinton, Dallas, Duarte, El Paso, Garner, Grand Rapids, Hackensack, Hattiesburg, Houston, Irvine, Las Vegas, Los Angeles, Mineola, Minneapolis, Mobile, Nashville, New Haven, New York, Norfolk, Olney, Orlando, Reno, Salt Lake City, San Antonio, San Francisco, Seattle, Silver Spring, Washington D.C., and West Palm Beach, United StatesSee the 39 sitesAlso in 34 other countries, 246 sites
Trial code
Registry title
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Status
Recruiting
Phase
Phase 3
People taking part
1,000 people, planned
Started
16 Mar 2025
Expected to end
18 May 2030
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sacituzumab tirumotecan
  • Pembrolizumab
  • Rescue Medication
  • Paclitaxel
  • Nab-paclitaxel
  • Gemcitabine
  • Carboplatin
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with triple-negative breast cancer that has come back or spread, cannot be removed by surgery, and has not yet had treatment for this stage. The tumour must have a PD-L1 CPS below 10.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Triple-negative breast cancer that has come back locally and cannot be removed by surgery, or has spread. It cannot be treated with treatment meant to remove all of the disease.
Earlier treatment
No earlier systemic treatment for the recurrent or spread cancer. Treatment for early-stage breast cancer must have ended at least 6 months before the cancer came back. Side effects from earlier treatments must have recovered to Grade 1 or baseline, apart from hair loss or vitiligo.
Biomarker or test result
Tumour PD-L1 expression with a combined positive score (CPS) below 10. Hepatitis B or C is allowed only if viral load is undetectable.

Main reasons for not taking part

  • PD-L1 CPS of 10 or higher
  • Earlier systemic treatment for recurrent or spread breast cancer
  • Active spread to the brain or spinal fluid linings, unless treated and stable
  • History of lung inflammation (pneumonitis or interstitial lung disease) needing steroids
  • Earlier stem cell or solid organ transplant

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Has locally recurrent unresectable or metastatic TNBC that cannot be treated with curative intent
  • Has not received systemic treatment for locally recurrent unresectable or metastatic breast cancer
  • Participants previously treated for early-stage breast cancer must have completed all prior therapy for early-stage breast cancer with curative intent at least 6 months before the first disease recurrence
  • Is a candidate for treatment with pembrolizumab and one of the TPC options: paclitaxel or nab-paclitaxel or gemcitabine + carboplatin
  • Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline with the exception of alopecia or vitiligo. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable

Who cannot take part

  • Has breast cancer amenable to treatment with curative intent
  • Has received prior systemic therapy for treatment of locally recurrent unresectable or metastatic breast cancer
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable
  • Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (HCV) (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection
  • Has not adequately recovered from major surgery or has ongoing surgical complications
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has skin only metastatic disease
  • Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments
  • History of stem cell/solid organ transplant
  • The main exclusion criteria include but are not limited to the following:
  • Has TNBC with evaluable tumor programmed death ligand 1 (PD-L1) expression at combined positive score (CPS) ≥10
  • Has Grade ≥2 peripheral neuropathy
  • Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications

Where in United States

Also in 34 other countries, 246 sites

  • New Mexico Oncology Hematology Consultants Ltd. (Site 0019)Albuquerque, United StatesContact: Study CoordinatorTaking people
  • AdventHealth Medical Group Oncology and Hematology at Altamonte (Site 0007)Altamonte Springs, United StatesContact: Study CoordinatorTaking people
  • University Cancer & Blood Center, LLC (Site 0023)Athens, United StatesContact: Study CoordinatorTaking people
  • MedStar Franklin Square Medical Center (Site 0031)Baltimore, United StatesContact: Study CoordinatorTaking people
  • MedStar Good Samaritan Hospital (Site 0079)Baltimore, United StatesContact: Study CoordinatorTaking people
  • St. Luke's Cancer Institute: Boise (Site 0037)Boise, United StatesContact: Study CoordinatorTaking people
  • Ironwood Cancer & Research Centers (Site 0036)Chandler, United StatesContact: Study CoordinatorTaking people
  • University of Illinois Cancer Center (Site 0044)Chicago, United StatesContact: Study CoordinatorTaking people
  • MedStar Southern Maryland Hospital Center (Site 0100)Clinton, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - DFW (Site 8007)Dallas, United StatesContact: Study CoordinatorTaking people
  • City of Hope (Site 0097)Duarte, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - West Texas (Site 8004)El Paso, United StatesContact: Study CoordinatorTaking people
  • Rex Hematology Oncology Associates - Garner (Site 0071)Garner, United StatesContact: Toll Free NumberNo longer taking part
  • Cancer & Hematology Centers of Western Michigan (Site 0026)Grand Rapids, United StatesContact: Study CoordinatorTaking people
  • John Theurer Cancer Center at Hackensack University Medical Center (Site 0082)Hackensack, United StatesContact: Study CoordinatorTaking people
  • Hattiesburg Clinic Hematology/Oncology (Site 0104)Hattiesburg, United StatesContact: Study CoordinatorTaking people
  • Kelsey-Seybold Clinic - North Houston Campus (Site 0096)Houston, United StatesContact: Study CoordinatorTaking people
  • Kelsey-Seybold Clinic (Site 0040)Houston, United StatesContact: Study CoordinatorTaking people
  • City of Hope Lennar Foundation Cancer Center (Site 0099)Irvine, United StatesContact: Study CoordinatorTaking people
  • Comprehensive Cancer Centers of Nevada (Site 0015)Las Vegas, United StatesContact: Study CoordinatorTaking people
  • UCLA Department of Medicine - Hematology & Oncology (Site 0047)Los Angeles, United StatesContact: Study CoordinatorTaking people
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island (Site 0073)Mineola, United StatesContact: Study CoordinatorTaking people
  • Allina Health Cancer Institute (Site 0069)Minneapolis, United StatesContact: Toll Free NumberNo longer taking part
  • USA Mitchell Cancer Institute (Site 0090)Mobile, United StatesContact: Study CoordinatorTaking people
  • SCRI Oncology Partners (Site 7004)Nashville, United StatesContact: Study CoordinatorTaking people
  • Tennessee Oncology (Site 0018)Nashville, United StatesContact: Study CoordinatorTaking people
  • Yale New Haven Hospital (Site 0001)New Haven, United StatesContact: Toll Free NumberNo longer taking part
  • Laura and Isaac Perlmutter Cancer Center (Site 0003)New York, United StatesContact: Study CoordinatorTaking people
  • Virginia Oncology Associates (VOA) (Site 8002)Norfolk, United StatesContact: Study CoordinatorTaking people
  • MedStar Montgomery Medical Center (Site 0078)Olney, United StatesContact: Study CoordinatorTaking people
  • Orlando Health Cancer Institute (Site 0012)Orlando, United StatesContact: Study CoordinatorTaking people
  • Renown Regional Medical Center (Site 0005)Reno, United StatesContact: Study CoordinatorTaking people
  • University of Utah, Huntsman Cancer Institute (Site 0056)Salt Lake City, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - San Antonio (Site 8001)San Antonio, United StatesContact: Study CoordinatorTaking people
  • UCSF Helen Diller Family Comprehensive Cancer Center (Site 0016)San Francisco, United StatesContact: Study CoordinatorTaking people
  • Fred Hutchinson Cancer Center (Site 0042)Seattle, United StatesContact: Study CoordinatorTaking people
  • Holy Cross Hospital (Site 0091)Silver Spring, United StatesContact: Study CoordinatorTaking people
  • Washington Hospital Center (Site 0098)Washington D.C., United StatesContact: Study CoordinatorTaking people
  • Florida Cancer Specialists - East (Site 7000)West Palm Beach, United StatesContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

The 3 groups in the trial

  • Arm A: Sacituzumab TirumotecanTreatment being tested

    Participants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) until disease progression, toxicity or discontinuation.

    Treatment: Sacituzumab tirumotecan and Rescue Medication

  • Arm B: Sacituzumab Tirumotecan + PembrolizumabTreatment being tested

    Participants receive sacituzumab tirumotecan IV 4 mg/kg Q2W until disease progression, toxicity or discontinuation PLUS pembrolizumab IV 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to \~2 years).

    Treatment: Sacituzumab tirumotecan, Pembrolizumab, and Rescue Medication

  • Arm C: Treatment of Physician's Choice (TPC)Existing treatment, for comparison

    Participants receive physician's choice of chemotherapy agent(s): paclitaxel IV 80 mg/m\^2 once every week (Q1W) OR paclitaxel IV 90 mg/m\^2 on Days 1, 8, and 15, every 4 weeks (Q4W) OR nab-paclitaxel IV 100 mg/m\^2 on Days 1, 8, and 15, Q4W OR gemcitabine IV 1000 mg/m\^2 on Days 1 and 8, every 3 weeks (Q3W) PLUS carboplatin IV area under the curve (AUC) 2 mg/mL/min on Days 1 and 8, Q3W, until disease progression, toxicity or discontinuation.

    Treatment: Paclitaxel, Nab-paclitaxel, Gemcitabine, and Carboplatin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)
Plain-language title
Tests sacituzumab tirumotecan for previously untreated triple-negative breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
10 November 2026